Skip to main content

Table 1 Clinical characteristics at baseline according to the PPARG genotype

From: Dietary polyunsaturated fatty acids and the Pro12Ala polymorphisms of PPARG regulate serum lipids through divergent pathways: a randomized crossover clinical trial

 

Pro12Pro (n = 17)

Ala12Ala (n = 14)

Baseline

Whole study

Mean

SD

Mean

SD

P

P

FDR§

Age (years)

56.7

7.2

62.1

7.3

0.048*

  

Weight (kg)

82.1

8.4

83.5

12.7

0.715

0.660

0.777

Body mass index (kg/m2)

26.0

2.4

26.9

3.4

0.406

0.271

0.492

Fasting plasma glucose (mmol/l)

5.8

0.4

5.7

0.5

0.857

0.479

0.713

Fasting plasma insulin (mU/l)

49.2

24.6

49.0

20.1

0.967

0.758

0.803

Fasting plasma FFA (mmol/l)

0.44

0.13

0.42

0.11

0.601

0.751

0.803

Total cholesterol (mmol/l)

5.38

0.81

4.81

0.81

0.062

0.003*

0.009*

HDL cholesterol (mmol/l)

1.24

0.25

1.52

0.45

0.039*

0.077

0.365

LDL cholesterol (mmol/l)

3.38

0.66

2.76

0.62

0.013*

2 × 10−4 *

9 × 10−4 *

Total triglycerides (mmol/l)

1.38

0.49

0.85

0.28

0.001*

4 × 10−4 *

0.001*

Apolipoprotein A1 (g/l)

1.39

0.17

1.43

0.24

0.596

0.661

0.777

Apolipoprotein B (g/l)

1.05

0.18

0.83

0.14

0.001*

2 × 10−5 *

3 × 10−4 *

  1. Whole study results are from mixed-model analysis for the genotype effect utilizing data from the whole duration of the study, adjusted for diet, phase, and week of the intervention
  2. Independent samples t test; Mixed-model analysis for the genotype effect, adjusted for diet, phase, and week of the intervention; § Mixed-model analysis P values FDR adjusted for multiple testing. Baseline measures were taken after habitual diet. * P < 0.05